Inspira Technologies OXY B.H.N. (IINN) Projected to Announce Earnings on Thursday

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) is expected to be issuing its results before the market opens on Thursday, August 6th. Analysts expect Inspira Technologies OXY B.H.N. to announce earnings of ($0.03) per share and revenue of $15.00 million for the quarter.

Inspira Technologies OXY B.H.N. Stock Performance

NASDAQ:IINN opened at $0.87 on Thursday. The stock has a 50-day moving average price of $1.57 and a 200 day moving average price of $0.93. Inspira Technologies OXY B.H.N. has a 12-month low of $0.34 and a 12-month high of $1.65. The company has a current ratio of 1.56, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inspira Technologies OXY B.H.N. stock. Citadel Advisors LLC acquired a new stake in shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 82,567 shares of the company’s stock, valued at approximately $105,000. Citadel Advisors LLC owned 0.65% of Inspira Technologies OXY B.H.N. at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.